Is QNCX or ENTX more profitable?

Entera Bio's return on equity of -83.31% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% Entera Bio N/A -83.31% -70.83%

Which has stronger earnings & valuation, QNCX or FLNA?

Cassava Sciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Quince Therapeutics N/A N/A -$83.98M -$10.62 N/A Cassava Sciences N/A N/A -$90.97M -$1.61 N/A

Is QNCX or FLNA more profitable?

Cassava Sciences' return on equity of -53.90% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% Cassava Sciences N/A -53.90% -34.20%

Is QNCX or EXOZ more profitable?

eXoZymes' return on equity of -220.63% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% eXoZymes N/A -220.63% -141.26%

Is QNCX or IMA more profitable?

ImageneBio's return on equity of -38.96% beat Quince Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Quince Therapeutics N/A -372.88% -67.99% ImageneBio N/A -38.96% -34.60%

Quince Therapeutics (QNCX) Competitors

$0.93 -0.02 (-1.85%)

Closing price 04:00 PM Eastern

Extended Trading

$0.92 -0.01 (-1.14%)

As of 07:59 PM Eastern

Compare

QNCX vs. ENTX, MNOV, FLNA, EXOZ, and IMA

Should you buy Quince Therapeutics stock or one of its competitors? MarketBeat compares Quince Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Quince Therapeutics include Entera Bio (ENTX), MediciNova (MNOV), Cassava Sciences (FLNA), eXoZymes (EXOZ), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry.

How does Quince Therapeutics compare to Entera Bio?

Quince Therapeutics (NASDAQ:QNCX) and Entera Bio (NASDAQ:ENTX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, media sentiment, valuation, profitability and risk.

Entera Bio has higher revenue and earnings than Quince Therapeutics. Entera Bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
Entera Bio	$40K	1,823.73	-$11.44M	-$0.27	N/A

Entera Bio's return on equity of -83.31% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
Entera Bio	N/A	-83.31%	-70.83%

Quince Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, Entera Bio has a beta of 1.56, meaning that its share price is 56% more volatile than the broader market.

Quince Therapeutics currently has a consensus price target of $65.00, indicating a potential upside of 6,907.33%. Entera Bio has a consensus price target of $9.00, indicating a potential upside of 508.11%. Given Quince Therapeutics' higher probable upside, analysts plainly believe Quince Therapeutics is more favorable than Entera Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 14.1% of Entera Bio shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by company insiders. Comparatively, 10.6% of Entera Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Entera Bio had 6 more articles in the media than Quince Therapeutics. MarketBeat recorded 6 mentions for Entera Bio and 0 mentions for Quince Therapeutics. Entera Bio's average media sentiment score of 0.50 beat Quince Therapeutics' score of 0.00 indicating that Entera Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Quince Therapeutics	Neutral
Entera Bio	Neutral

Summary

Entera Bio beats Quince Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Quince Therapeutics compare to MediciNova?

Quince Therapeutics (NASDAQ:QNCX) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Quince Therapeutics has a net margin of 0.00% compared to MediciNova's net margin of -1,962.98%. MediciNova's return on equity of -27.28% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
MediciNova	-1,962.98%	-27.28%	-25.24%

Quince Therapeutics currently has a consensus price target of $65.00, suggesting a potential upside of 6,907.33%. MediciNova has a consensus price target of $8.33, suggesting a potential upside of 541.03%. Given Quince Therapeutics' higher probable upside, equities research analysts plainly believe Quince Therapeutics is more favorable than MediciNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
MediciNova	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Quince Therapeutics has a beta of 1.4, meaning that its share price is 40% more volatile than the broader market. Comparatively, MediciNova has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

In the previous week, MediciNova had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 1 mentions for MediciNova and 0 mentions for Quince Therapeutics. MediciNova's average media sentiment score of 0.59 beat Quince Therapeutics' score of 0.00 indicating that MediciNova is being referred to more favorably in the news media.

Company	Overall Sentiment
Quince Therapeutics	Neutral
MediciNova	Positive

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 9.9% of MediciNova shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by company insiders. Comparatively, 14.0% of MediciNova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

MediciNova has higher revenue and earnings than Quince Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
MediciNova	$410K	156.06	-$12M	-$0.23	N/A

Summary

MediciNova beats Quince Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Quince Therapeutics compare to Cassava Sciences?

Quince Therapeutics (NASDAQ:QNCX) and Cassava Sciences (NASDAQ:FLNA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

Cassava Sciences' return on equity of -53.90% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
Cassava Sciences	N/A	-53.90%	-34.20%

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 38.1% of Cassava Sciences shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Quince Therapeutics' average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Quince Therapeutics	Neutral
Cassava Sciences	Neutral

Quince Therapeutics presently has a consensus target price of $65.00, indicating a potential upside of 6,907.33%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 303.23%. Given Quince Therapeutics' higher probable upside, equities analysts clearly believe Quince Therapeutics is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Cassava Sciences is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$1.61	N/A

Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.72, indicating that its share price is 172% less volatile than the broader market.

Summary

Cassava Sciences beats Quince Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Quince Therapeutics compare to eXoZymes?

Quince Therapeutics (NASDAQ:QNCX) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

eXoZymes has higher revenue and earnings than Quince Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
eXoZymes	$70K	990.95	-$9.16M	-$1.14	N/A

eXoZymes' return on equity of -220.63% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
eXoZymes	N/A	-220.63%	-141.26%

In the previous week, eXoZymes had 2 more articles in the media than Quince Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Quince Therapeutics	Neutral
eXoZymes	Neutral

Quince Therapeutics currently has a consensus price target of $65.00, indicating a potential upside of 6,907.33%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Quince Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.66, indicating that its share price is 166% more volatile than the broader market.

30.8% of Quince Therapeutics shares are owned by institutional investors. 7.1% of Quince Therapeutics shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

eXoZymes beats Quince Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Quince Therapeutics compare to ImageneBio?

Quince Therapeutics (NASDAQ:QNCX) and ImageneBio (NASDAQ:IMA) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

ImageneBio has higher revenue and earnings than Quince Therapeutics. ImageneBio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
ImageneBio	$800K	79.74	-$45.35M	-$5.79	N/A

ImageneBio's return on equity of -38.96% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
ImageneBio	N/A	-38.96%	-34.60%

In the previous week, ImageneBio had 1 more articles in the media than Quince Therapeutics. MarketBeat recorded 1 mentions for ImageneBio and 0 mentions for Quince Therapeutics. Quince Therapeutics' average media sentiment score of 0.00 equaled ImageneBio'saverage media sentiment score.

Company	Overall Sentiment
Quince Therapeutics	Neutral
ImageneBio	Neutral

Quince Therapeutics presently has a consensus target price of $65.00, suggesting a potential upside of 6,907.33%. ImageneBio has a consensus target price of $26.50, suggesting a potential upside of 342.40%. Given Quince Therapeutics' higher probable upside, research analysts clearly believe Quince Therapeutics is more favorable than ImageneBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
ImageneBio	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.00

Quince Therapeutics has a beta of 1.4, indicating that its share price is 40% more volatile than the broader market. Comparatively, ImageneBio has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market.

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 75.0% of ImageneBio shares are held by institutional investors. 7.1% of Quince Therapeutics shares are held by insiders. Comparatively, 2.2% of ImageneBio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

ImageneBio beats Quince Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Quince Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QNCX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

QNCX vs. The Competition

Export

Metric	Quince Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.41M	$3.41B	$6.42B	$12.54B
Dividend Yield	N/A	2.32%	2.68%	5.81%
P/E Ratio	-0.09	19.52	24.98	24.33
Price / Sales	N/A	330.92	529.24	114.75
Price / Cash	N/A	56.54	27.92	37.84
Price / Book	-0.14	8.34	10.85	6.58
Net Income	-$83.98M	$23.80M	$3.56B	$336.75M
7 Day Performance	-0.37%	3.63%	0.70%	-0.49%
1 Month Performance	-15.67%	1.77%	0.29%	1.56%
1 Year Performance	-92.86%	58.60%	30.68%	33.78%

Quince Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
QNCX Quince Therapeutics	1.3189 of 5 stars	$0.93 -1.9%	$65.00 +6,907.3%	-92.7%	$15.41M	N/A	N/A	60	Gap Down
ENTX Entera Bio	2.4098 of 5 stars	$1.21 -1.6%	$9.00 +643.8%	-38.9%	$60.63M	$40K	N/A	20	News Coverage Gap Up Trading Halted
MNOV MediciNova	1.9862 of 5 stars	$1.25 +1.6%	$8.33 +566.7%	+2.3%	$60.54M	$410K	N/A	10	News Coverage Gap Up High Trading Volume
FLNA Cassava Sciences	1.4942 of 5 stars	$1.21 -3.2%	$5.00 +313.2%	-38.7%	$60.38M	N/A	N/A	20
EXOZ eXoZymes	0.2244 of 5 stars	$7.35 +3.5%	N/A	-14.4%	$60.20M	$70K	N/A	29

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:QNCX) was last updated on 6/22/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Quince Therapeutics (QNCX) Competitors

QNCX vs. ENTX, MNOV, FLNA, EXOZ, and IMA

How does Quince Therapeutics compare to Entera Bio?

Summary

How does Quince Therapeutics compare to MediciNova?

Summary

How does Quince Therapeutics compare to Cassava Sciences?

Summary

How does Quince Therapeutics compare to eXoZymes?

Summary

How does Quince Therapeutics compare to ImageneBio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Quince Therapeutics (QNCX) Competitors

QNCX vs. ENTX, MNOV, FLNA, EXOZ, and IMA

How does Quince Therapeutics compare to Entera Bio?

Which has higher valuation & earnings, QNCX or ENTX?

Is QNCX or ENTX more profitable?

Which has more risk and volatility, QNCX or ENTX?

Do analysts prefer QNCX or ENTX?

Do institutionals and insiders believe in QNCX or ENTX?

Does the media favor QNCX or ENTX?

Summary

How does Quince Therapeutics compare to MediciNova?

Is QNCX or MNOV more profitable?

Do analysts prefer QNCX or MNOV?

Which has more risk & volatility, QNCX or MNOV?

Does the media refer more to QNCX or MNOV?

Do insiders & institutionals have more ownership in QNCX or MNOV?

Which has preferable valuation & earnings, QNCX or MNOV?

Summary

How does Quince Therapeutics compare to Cassava Sciences?

Is QNCX or FLNA more profitable?

Do institutionals and insiders have more ownership in QNCX or FLNA?

Does the media favor QNCX or FLNA?

Do analysts recommend QNCX or FLNA?

Which has stronger earnings & valuation, QNCX or FLNA?

Which has more risk & volatility, QNCX or FLNA?

Summary

How does Quince Therapeutics compare to eXoZymes?

Which has better valuation & earnings, QNCX or EXOZ?

Is QNCX or EXOZ more profitable?

Does the media favor QNCX or EXOZ?

Do analysts recommend QNCX or EXOZ?

Which has more volatility & risk, QNCX or EXOZ?

Do institutionals & insiders have more ownership in QNCX or EXOZ?

Summary

How does Quince Therapeutics compare to ImageneBio?

Which has better earnings & valuation, QNCX or IMA?

Is QNCX or IMA more profitable?

Does the media refer more to QNCX or IMA?

Do analysts recommend QNCX or IMA?

Which has more risk and volatility, QNCX or IMA?

Do insiders & institutionals hold more shares of QNCX or IMA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNCX vs. The Competition

Quince Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools